Therefore, both V-ATPase and HIF-1α provide effective therapeutic targets, and reducing the expression of V-ATPase and HIF-1α can increase the effectiveness of chemotherapeutic drugs and even reverse the drug resistance of gastric cancer cells (Chen et al., 2012). The gene discussed is HIF1A; the disease is gastric cancer.